pectin doxorubicin

Pectin doxorubicin (also known as pectin-adriamycin conjugate or PAC) is an investigational polymer-drug conjugate developed by Sichuan Enray Pharmaceutical Sciences (Sichuan Yingrui Pharmaceutical Technology) for the treatment of various solid tumors. The drug consists of the anthracycline chemotherapeutic agent doxorubicin covalently linked to pectin, a natural polysaccharide, via a hydrolysable peptide linker. This conjugation is designed to exploit the enhanced permeability and retention (EPR) effect for passive tumor targeting, thereby increasing the concentration of doxorubicin within tumor tissues while minimizing systemic toxicities, particularly cardiotoxicity. Once inside the tumor microenvironment, the linker is cleaved to release active doxorubicin, which intercalates into DNA and inhibits topoisomerase II, leading to DNA crosslinking and tumor cell death.

Other names

Pectin doxorubicinPectin-adriamycin conjugatePectin-doxorubicin conjugate果胶-阿霉素偶联物果胶-阿霉素轭合物果胶阿霉素